CAJ | 학술논문

目的：探讨米氮平治疗抑郁症的疗效及安全性．方法：将内蒙古民族大学附属医院心理治疗与咨询门诊自2007—11-2011-11收治的76例抑郁症患者随机分为两组，米氮平治疗38例为治疗组，帕罗西汀治疗38例为对照组，疗程12周，以汉密尔顿抑郁量表（HAMD）评定疗效，以抗抑郁药副反应量表（SERS）评定不良反应，分别在治疗前和治疗后2、12周末评定一次．结果：两组治疗前HAMD及瘸晴严重程度评分均无显著性差异（P〉0．05），治疗2、12周末两组HAMD评分与治疗前比较均显著下降（P〈0．05）．治疗2周末，HAMD评分两组间比较有非常显著差异（P〈0．01）；治疗12周末，两组间HAMD评分无显著差异（P〉0．05）．治疗2周末，治疗组不良反应有食欲增加6例，口干2例，嗜睡3例，头晕3例；对照组恶心8例，口干6例，头晕、乏力各4例，心烦、坐不住3例．治疗12周末，治疗组不良反应有体重增加2例，对照组性功能障碍1例．结论：米氮平治疗抑郁症疗效可靠，且起效快、不良反应较轻．
목적：탐토미담평치료억욱증적료효급안전성．방법：장내몽고민족대학부속의원심리치료여자순문진자2007—11-2011-11수치적76례억욱증환자수궤분위량조，미담평치료38례위치료조，파라서정치료38례위대조조，료정12주，이한밀이돈억욱량표（HAMD）평정료효，이항억욱약부반응량표（SERS）평정불량반응，분별재치료전화치료후2、12주말평정일차．결과：량조치료전HAMD급가청엄중정도평분균무현저성차이（P〉0．05），치료2、12주말량조HAMD평분여치료전비교균현저하강（P〈0．05）．치료2주말，HAMD평분량조간비교유비상현저차이（P〈0．01）；치료12주말，량조간HAMD평분무현저차이（P〉0．05）．치료2주말，치료조불량반응유식욕증가6례，구간2례，기수3례，두훈3례；대조조악심8례，구간6례，두훈、핍력각4례，심번、좌불주3례．치료12주말，치료조불량반응유체중증가2례，대조조성공능장애1례．결론：미담평치료억욱증료효가고，차기효쾌、불량반응교경．
Objective: To investigate the efficacy and safety of mirtazapine in the treatment of depression. Methods: 76 patients with depression, who treated at psychological treatment and counseling outpatient of affiliated hospital of Inner Mongolia University for Nationalities from November 2007 to November 2011, were randomly divided into treatment group(38 cases) and control group(38 cases), the treatment group were treated with mirtazapine, and the control group were treated with paroxetine, the treatment course was 12 weeks. Adopting Hamilton rating scale for depression(HAMD) to assess the efficacy, rating scale for side effects(SERS) to assess side effects, the assessments were made before treatment and after treatment 2 and 12 weeks respectively. Results: HAMD and disease severity scores of the two groups before treatment had no significant difference (P〉0.05). After treatment for 2 and 12 weeks, HAMD scores of the two groups were significantly decreased compared with pretreatment(P〈O.05), and there was a significant difference between the two groups (P〈O.01); while after treatment 12 weeks, HAMD score between the two groups had no significant difference (P〉0.05). After 2 weeks treatment, adverse effects in the treatment group: appetite increase in 6 cases, dry mouth in 2 cases, lethargy in 3 cases, dizziness in 3 cases; in the control group: nausea in 8 cases, dry mouth in 6 cases, dizziness in 4 cases, hypodynamia in 4 cases, restlessness in 3 cases. The adve~e effects after 12 weeks treatment, there were 2 cases of gain weight in the treatment group, 1 case of sexual dysfunction in the control group. Conclusion: Mirtazapine has a reliable effect in treating depression with rapid effect and lighter adverse reactions.